| Category | Details |
| Definition | Chronic pain is a persistent pain lasting over three months, often associated with conditions like neuropathic pain, arthritis, or fibromyalgia. |
| Global Epidemiology | – Affects over 1.5 billion people globally. |
| – Neuropathic pain affects 7–10% of the population, with up to 25% of chronic pain cases. | |
| – High prevalence among elderly and individuals with chronic conditions. | |
| Prevalence in Key Regions | – United States: ~20% of adults (~50 million) report chronic pain. |
| – European Union: Estimated 19% prevalence (~90 million individuals). | |
| – Canada: Affects ~18% of adults (~6.4 million people). | |
| – Caribbean: Prevalence estimated at 20–25%, reflecting ~10–15 million cases. | |
| Medicinal Cannabis Approvals | – United States (FDA): No specific approval, but cannabinoids used for neuropathic pain (e.g., dronabinol). |
| – European Union (EMA): Nabiximols (Sativex) approved in 2010 for spasticity; studied off-label for chronic pain. | |
| – Canada: Approved nabiximols since 2012 for chronic pain and spasticity. Nabiximols (Sativex) was approved by Health Canada for the treatment of spasticity due to multiple sclerosis in 2010. It was subsequently licensed with conditions for additional uses, including as an adjunctive treatment for neuropathic pain associated with multiple sclerosis and for pain due to cancer | |
| – Australia (TGA): Approved nabiximols and dronabinol for pain since 2015. Approval of Nabiximols:Nabiximols (Sativex) was approved by the TGA for use in Australia, specifically for spasticity due to multiple sclerosis. It was listed on the Australian Register of Therapeutic Goods (ARTG) in 2010. While it has been studied for its efficacy in managing chronic pain, its primary indication remains spasticity, and it is not specifically approved for general chronic pain management . Dronabinol Approval:Dronabinol, a synthetic form of THC, is not listed as a TGA-approved product specifically for pain management. While it may be used in clinical settings, it is generally available under special access schemes rather than having formal approval for specific indications like chronic pain . Use in Chronic Pain:Both nabiximols and dronabinol have been studied for their potential benefits in chronic pain management, particularly in neuropathic pain and cancer-related pain. However, the evidence supporting their effectiveness is mixed, and they are not first-line treatments according to TGA guidelines . | |
| – Israel: Medical cannabis authorized for chronic pain since 2013. | |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Anti-inflammatory and neuroprotective effects, reduces pain and hypersensitivity. |
| – THC (Tetrahydrocannabinol): Effective for neuropathic pain relief; psychoactive effects noted. | |
| – THCV (Tetrahydrocannabivarin): Experimental evidence for reducing hypersensitivity and improving pain modulation. | |
| – CBG (Cannabigerol): Emerging role in anti-inflammatory and analgesic pathways. | |
| – Delta-8-THC: Similar to THC but with lower psychoactive effects; potential for pain relief. | |
| Mechanism of Action | – Modulation of CB1 and CB2 receptors to reduce central and peripheral sensitization. |
| – CBD reduces inflammation and oxidative stress, key drivers in chronic pain. | |
| – THC acts on CB1 to alter pain perception and emotional response to pain. | |
| Key Clinical Studies | – Finnerup et al., 2020: Systematic review found cannabinoids effective for neuropathic pain (30% relief in 1 in 5 patients). |
| – Mücke et al., 2018: Nabiximols reduced pain intensity in chronic neuropathic pain patients. | |
| – Andreae et al., 2015: Inhaled cannabis improved neuropathic pain symptoms in 20% of participants. | |
| – Dykukha et al., 2021: Nabiximols significantly reduced spasticity-related pain | |
| – Petzke et al., 2021: Meta-analysis indicated cannabinoids as a third-line treatment for chronic neuropathic pain. | |
| Dosage Guidelines | – Nabiximols (Sativex): Up to 12 sprays/day; each spray contains 2.7 mg THC and 2.5 mg CBD. |
| – CBD (Oral): Initial dose 5–10 mg/day; titrate to 20–50 mg/day based on response. | |
| – THC (Inhaled): Start at 1–2 mg/day; gradual increase as tolerated. | |
| – CBG/THCV (Experimental): Early trials suggest 10–20 mg/day for pain modulation. | |
| Administration Methods | – Sublingual Spray (Nabiximols): Rapid absorption; preferred for acute pain episodes. |
| – Oral Capsules: Slower onset but consistent dosing; suitable for chronic pain. | |
| – Inhalation: Rapid relief but variable dosing; not preferred for long-term management. | |
| Adverse Effects | – CBD: Mild side effects include fatigue, diarrhea, and appetite changes; rare liver enzyme elevation. |
| – THC: Dizziness, anxiety, cognitive impairment, and risk of dependence. | |
| – Nabiximols: Common effects include dizziness, dry mouth, and fatigue; rare psychosis. | |
| Research Gaps | – Long-term safety and efficacy studies for cannabinoids in chronic pain management are needed. |
| – Limited data on interaction of cannabinoids with standard analgesics and opioids. | |
| Opportunities in the Caribbean | – High Prevalence: Estimated 20–25% of the population suffer from chronic pain, often untreated due to healthcare access barriers. |
| – Cannabis Clinics: Establishing specialized clinics could address local and regional needs and attract medical tourists. | |
| – Research Hub: Opportunities for cannabinoid-focused research could position the Caribbean as a leader in pain management innovation. |
